novartis glp-1 receptor agonist weight management diabetes treatments of type 2 with the dual GIP/GLP-1 tirzepatide: a systematic review and meta-analysis | Diabetologia novartis glp-1 receptor agonist weight

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

There is no argument that the drugs are much more potent and faster acting than your bodies natural GLP-1 hormones

This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database

Mattioli Introduction GLP-1 agonists like liraglutide have become a powerful tool for weight management, but they often come with digestive side effects and concerns about long-term use

GLP-1 is a peptide hormone secreted by L cells in the ileum and colon